SCHEMBL3817090

SCHEMBL3817090

CC(c1nc2ccc(Br)cc2c(=O)n1C)N1CCN(S(=O)(=O)c2ccc(Br)cc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 2/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ GPR183 P32249 2/20 0.41
▸ GBA1 P04062 1/20 0.41
▸ CACNA2D1 P54289 7/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ LMNA P02545 2/20 0.39
▸ GAA P10253 2/20 0.39
▸ GLA P06280 1/20 0.39
▸ ADORA2B P29275 1/20 0.38
▸ OPRM1 P35372 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ CFTR P13569 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3820657 0.95 GAA (0.47) PKMRXFP1GBA1CACNA2D1LMNA
SCHEMBL3822489 0.95 PKM (0.47) PKMRXFP1GBA1CACNA2D1L3MBTL1
SCHEMBL3821683 0.94 GBA1 (0.44) PKMRXFP1GBA1CACNA2D1L3MBTL1
SCHEMBL3824315 0.93 PKM (0.40) PKMRXFP1GPR183GBA1L3MBTL1
SCHEMBL3819087 0.93 CFTR (0.47) PKMGPR183GBA1LMNAKDM4E
SCHEMBL3825392 0.92 PKM (0.39) PKMRXFP1GPR183GBA1L3MBTL1
SCHEMBL15457092 0.92 PKM (0.43) PKMGPR183GBA1L3MBTL1LMNA
SCHEMBL15457174 0.91 CFTR (0.46) PKMGPR183GBA1L3MBTL1LMNA
SCHEMBL15457101 0.90 GBA1 (0.50) PKMGBA1CACNA2D1L3MBTL1LMNA
SCHEMBL3820231 0.89 ALDH1A1 (0.40) PKMRXFP1GPR183GBA1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 — — US disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 — — US disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 — — US disclosed
EP-1646615-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2009-08-26 — — EP disclosed
EP-1646615-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2009-08-26 — — EP disclosed
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2005-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters CFTR, ABCB1, ABCC2 PKM 2518/4885RXFP1 1324/4885GPR183 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback